HRP20220648T1 - Biciklički inhibitori histonske deacetilaze - Google Patents
Biciklički inhibitori histonske deacetilaze Download PDFInfo
- Publication number
- HRP20220648T1 HRP20220648T1 HRP20220648TT HRP20220648T HRP20220648T1 HR P20220648 T1 HRP20220648 T1 HR P20220648T1 HR P20220648T T HRP20220648T T HR P20220648TT HR P20220648 T HRP20220648 T HR P20220648T HR P20220648 T1 HRP20220648 T1 HR P20220648T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pharmaceutically acceptable
- image
- acceptable salt
- formula
- Prior art date
Links
- 102000003964 Histone deacetylase Human genes 0.000 title 1
- 108090000353 Histone deacetylase Proteins 0.000 title 1
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 13
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 5
- 208000020358 Learning disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 201000003723 learning disability Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000031888 Mycoses Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 230000007000 age related cognitive decline Effects 0.000 claims 2
- 230000008033 biological extinction Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 206010039281 Rubinstein-Taybi syndrome Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 230000001143 conditioned effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013932 dyslexia Diseases 0.000 claims 1
- 230000014061 fear response Effects 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 230000006386 memory function Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (15)
1. Spoj formule:
[image]
[image]
; ili
[image]
ili njegova farmaceutski prihvatljiva sol.
2. Spoj prema zahtjevu 1, pri čemu je spoj formule:
[image]
ili njegova farmaceutski prihvatljiva sol.
3. Spoj prema zahtjevu 1, pri čemu je spoj formule:
[image]
ili njegova farmaceutski prihvatljiva sol.
4. Spoj prema zahtjevu 1, pri čemu je spoj formule:
[image]
ili njegova farmaceutski prihvatljiva sol.
5. Spoj prema zahtjevu 1, pri čemu je spoj formule:
[image]
ili njegova farmaceutski prihvatljiva sol.
6. Spoj prema zahtjevu 1, pri čemu je spoj formule:
[image]
ili njegova farmaceutski prihvatljiva sol.
7. Spoj prema zahtjevu 1, pri čemu je spoj formule:
[image]
ili njegova farmaceutski prihvatljiva sol.
8. Spoj prema zahtjevu 1, pri čemu je spoj formule:
[image]
ili njegova farmaceutski prihvatljiva sol.
9. Spoj prema zahtjevu 1, pri čemu je spoj formule:
[image]
ili njegova farmaceutski prihvatljiva sol.
10. Spoj prema zahtjevu 1, pri čemu je spoj formule:
[image]
ili njegova farmaceutski prihvatljiva sol.
11. Spoj prema zahtjevu 1, pri čemu je spoj formule:
[image]
ili njegova farmaceutski prihvatljiva sol.
12. Farmaceutski sastav koji obuhvaća: spoj prema bilo kojem od zahtjeva 1 do 11, ili njegovu farmaceutski prihvatljivu sol; i farmaceutski prihvatljiv nosač.
13. Spoj prema bilo kojem od zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, za upotrebu u liječenju stanja kod subjekta odabranog između neurološkog poremećaja, poremećaja pamćenja ili kognitivnih funkcija ili oštećenja, poremećaja ekstincijskog učenja, gljivične bolesti ili infekcije, inflamatorne bolesti, hematološke bolesti, psihijatrijskih poremećaja, i neoplastične bolesti.
14. Spoj za upotrebu prema zahtjevu 13, pri čemu je stanje:
a. poremećaj kognitivnih funkcija ili oštećenje udruženo s Alzheimerovom bolešću, Huntingtonova bolest, napadom induciran gubitak pamćenja, shizofrenija, Rubinstein Taybi sindrom, Rettov sindrom, fragilni X, demencija Lewyjevih tjelešaca, vaskularna demencija, frontotemporalna demencija, ADHD, disleksija, bipolarni poremećaj i socijalni, kognitivni i poremećaji učenja udruženi s autizmom, traumatična ozljeda glave, poremećaj nedostatka pažnje, anksiozni poremećaj, uvjetovani odgovor na strah, panični poremećaj, opsesivno kompulzivni poremećaj, posttraumatski stresni poremećaj (PTSD), fobija, socijalni anksiozni poremećaj, oporavak ovisnosti o supstanci, oštećenje pamćenja povezano sa starenjem (AAMI), kognitivni pad povezan sa starenjem (ARCD), ataksija, ili Parkinsonova bolest; ili
b. hematološka bolest odabrana između akutne mijeloične leukemije, akutne promijelocitne leukemije, akutne limfoblastne leukemije, kronične mijeloične leukemije, mijelodisplastičnih sindroma, i anemije srpastih ćelija; ili
c. neoplastična bolest; ili
d. poremećaj ekstinkcijskog učenja odabran između gubitka straha i posttraumatskog stresnog poremećaja.
15. Spoj za upotrebu prema zahtjevu 14, pri čemu je stanje Alzheimerova bolest, Huntingtonovaa bolest, frontotemporalna demencija, Freidreichovaataksija, posttraumatski stresni poremećaj (PTSD), Parkinsonova bolest, ili oporavak ovisnosti osupstanci.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541807P | 2017-08-07 | 2017-08-07 | |
| EP18759502.0A EP3664802B1 (en) | 2017-08-07 | 2018-08-07 | Bicyclic inhibitors of histone deacetylase |
| PCT/US2018/045528 WO2019032528A1 (en) | 2017-08-07 | 2018-08-07 | BICYCLIC HISTONE DEACETYLASE INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220648T1 true HRP20220648T1 (hr) | 2022-09-02 |
Family
ID=63364199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220648TT HRP20220648T1 (hr) | 2017-08-07 | 2018-08-07 | Biciklički inhibitori histonske deacetilaze |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11225475B2 (hr) |
| EP (1) | EP3664802B1 (hr) |
| JP (1) | JP7152471B2 (hr) |
| KR (1) | KR20200037286A (hr) |
| CN (1) | CN111032040B (hr) |
| AU (1) | AU2018313094A1 (hr) |
| CA (1) | CA3071861A1 (hr) |
| DK (1) | DK3664802T3 (hr) |
| EA (1) | EA039417B1 (hr) |
| ES (1) | ES2914355T3 (hr) |
| HR (1) | HRP20220648T1 (hr) |
| HU (1) | HUE058799T2 (hr) |
| IL (1) | IL272479B2 (hr) |
| LT (1) | LT3664802T (hr) |
| MA (1) | MA49839B1 (hr) |
| MD (1) | MD3664802T2 (hr) |
| MX (1) | MX2020001484A (hr) |
| PL (1) | PL3664802T3 (hr) |
| PT (1) | PT3664802T (hr) |
| RS (1) | RS63343B1 (hr) |
| SG (1) | SG11202000970WA (hr) |
| SI (1) | SI3664802T1 (hr) |
| WO (1) | WO2019032528A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62639B1 (sr) | 2015-07-06 | 2021-12-31 | Alkermes Inc | Hetero-halo inhibitori histonskih deacetilaza |
| AU2018207402B2 (en) | 2017-01-11 | 2023-09-28 | Alkermes, Inc. | Bicyclic inhibitors of histone deacetylase |
| EP3664802B1 (en) | 2017-08-07 | 2022-02-23 | Alkermes, Inc. | Bicyclic inhibitors of histone deacetylase |
| WO2021117759A1 (ja) * | 2019-12-10 | 2021-06-17 | 塩野義製薬株式会社 | 含窒素芳香族複素環式基を有するヒストン脱アセチル化酵素阻害剤 |
Family Cites Families (295)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5112824A (en) | 1989-12-08 | 1992-05-12 | Merck & Co., Inc. | Benzofuran compounds as class III antiarrhythmic agents |
| FR2665159B1 (fr) | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| DE4212748A1 (de) | 1992-04-16 | 1993-10-21 | Thomae Gmbh Dr K | Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| GB9420521D0 (en) | 1994-10-12 | 1994-11-30 | Smithkline Beecham Plc | Novel compounds |
| GB9420999D0 (en) | 1994-10-18 | 1994-12-07 | Smithkline Beecham Plc | Novel compounds |
| AU4515896A (en) | 1994-12-12 | 1996-07-03 | Merck & Co., Inc. | Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase |
| GB9500580D0 (en) | 1995-01-12 | 1995-03-01 | Merck Sharp & Dohme | Therapeutic agents |
| HU223601B1 (hu) | 1995-02-02 | 2004-10-28 | Smithkline Beecham P.L.C. | 5-HT receptor antagonista indolszármazékok |
| US5668148A (en) | 1995-04-20 | 1997-09-16 | Merck & Co., Inc. | Alpha1a adrenergic receptor antagonists |
| GB9517559D0 (en) | 1995-08-26 | 1995-10-25 | Smithkline Beecham Plc | Novel compounds |
| US5886186A (en) | 1995-10-25 | 1999-03-23 | Versicor, Inc. | Synthesis of substituted N-heteroaromatic compounds and methods of use thereof |
| US5872136A (en) | 1996-04-03 | 1999-02-16 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
| JP2000507590A (ja) | 1996-04-03 | 2000-06-20 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質トランスフェラーゼ阻害剤 |
| FR2763944B1 (fr) | 1997-06-03 | 2000-12-15 | Centre Nat Rech Scient | Nouveaux derives de coumarines, leurs procedes de preparation et leur application comme medicaments en tant qu'inhibiteurs de proteases |
| JPH1149676A (ja) | 1997-07-31 | 1999-02-23 | Geron Corp | ピリジン系テロメラーゼ阻害剤 |
| JPH11209366A (ja) | 1998-01-23 | 1999-08-03 | Nissan Chem Ind Ltd | クロマン誘導体及び心不全治療薬 |
| EP1087963B1 (en) | 1998-06-19 | 2004-08-25 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| AR019190A1 (es) | 1998-07-08 | 2001-12-26 | Sod Conseils Rech Applic | Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos |
| DE60030097T2 (de) | 1999-03-16 | 2007-03-08 | Cytovia, Inc., San Diego | Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung |
| GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| DE60118004T2 (de) | 2000-08-14 | 2006-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Substituierte pyrazole |
| KR100818056B1 (ko) | 2000-09-06 | 2008-03-31 | 오르토-맥네일 파마슈티칼, 인코퍼레이티드 | 치환된 피라졸을 포함하는 알레르기 치료용 약제 |
| WO2002026708A1 (fr) | 2000-09-27 | 2002-04-04 | Toray Industries, Inc. | Composes conenant de l'azote et inhibiteurs de ccr3 contenant ces composes en tant que principe actif |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| RU2003120061A (ru) | 2000-12-07 | 2004-11-27 | Си Ви Терапьютикс, Инк. (Us) | Замещенные 1,3,5-триазины и пиримидины в качестве повышающих авса-1 соединений против заболевания коронарной артерии или атеросклероза |
| EP1353674A1 (en) | 2000-12-29 | 2003-10-22 | Alteon, Inc. | Method for treating glaucoma ivb |
| ATE375340T1 (de) | 2001-02-21 | 2007-10-15 | Nps Pharma Inc | Heteropolycyclische verbindungen und deren verwendung als metabotrope glutamatrezeptorantagonisten |
| US6858600B2 (en) | 2001-05-08 | 2005-02-22 | Yale University | Proteomimetic compounds and methods |
| WO2003042190A1 (en) | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| TW200301698A (en) | 2001-12-21 | 2003-07-16 | Bristol Myers Squibb Co | Acridone inhibitors of IMPDH enzyme |
| JP2003192673A (ja) | 2001-12-27 | 2003-07-09 | Bayer Ag | ピペラジンカルボキシアミド誘導体 |
| EP1467986A1 (en) | 2002-01-17 | 2004-10-20 | Eli Lilly And Company | Aza-cyclic compounds as modulators of acetylcholine receptors |
| JP4167848B2 (ja) | 2002-04-10 | 2008-10-22 | 広栄化学工業株式会社 | ビアリール化合物の製造法 |
| CN1181065C (zh) | 2002-05-08 | 2004-12-22 | 上海医药工业研究院 | 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用 |
| US20040082627A1 (en) | 2002-06-21 | 2004-04-29 | Darrow James W. | Certain aromatic monocycles as kinase modulators |
| AU2003249369A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
| BR0313397A (pt) | 2002-08-14 | 2005-06-28 | Vertex Pharmaceuticals Incorpo | Inibidores de proteina cinase e usos destes |
| US7632858B2 (en) | 2002-11-15 | 2009-12-15 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
| US20040248850A1 (en) | 2003-02-11 | 2004-12-09 | Kemia, Inc. | Compounds for the treatment of HIV infection |
| CL2004000234A1 (es) | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
| NZ544009A (en) | 2003-07-24 | 2009-07-31 | Euro Celtique Sa | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain |
| TWI287567B (en) | 2003-07-30 | 2007-10-01 | Chi Mei Optoelectronics Corp | Light-emitting element and iridium complex |
| CA2534905A1 (en) | 2003-08-08 | 2005-02-17 | Janssen Pharmaceutica, N.V. | Pyridyl piperazinyl ureas |
| CA2535665A1 (en) | 2003-08-14 | 2005-02-24 | Asahi Kasei Pharma Corporation | Substituted arylalkanoic acid derivative and use thereof |
| US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| WO2005030704A1 (en) | 2003-09-24 | 2005-04-07 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| AU2005215379A1 (en) | 2004-02-12 | 2005-09-01 | Merck & Co., Inc. | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 |
| CN1989131A (zh) | 2004-03-30 | 2007-06-27 | 希龙公司 | 取代的噻吩衍生物用作抗癌药 |
| JP4777974B2 (ja) | 2004-04-01 | 2011-09-21 | イーライ リリー アンド カンパニー | ヒスタミンｈ３受容体作用物質、製剤および治療的使用 |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| FR2869904B1 (fr) | 2004-05-07 | 2006-07-28 | Fournier S A Sa Lab | Modulateurs des recepteurs lxr |
| ATE432926T1 (de) | 2004-07-26 | 2009-06-15 | Lilly Co Eli | Oxazolderivate als histamin-h3-rezeptor- wirkstoffe, deren herstellung und therapeutische verwendung |
| EP1802606B1 (en) | 2004-10-19 | 2011-03-16 | Compass Pharmaceuticals LLC | Arylcarboxamides and their use as anti-tumor agents |
| JP2008519814A (ja) | 2004-11-12 | 2008-06-12 | ガラパゴス・ナムローゼ・フェンノートシャップ | プロテインキナーゼ酵素の活性部位と結合する窒素複素環式芳香族化合物 |
| EP1824821A2 (en) | 2004-11-23 | 2007-08-29 | PTC Therapeutics, Inc. | Carbazole, carboline and indole derivatives useful in the inhibition of vegf production |
| UY29300A1 (es) | 2004-12-22 | 2006-07-31 | Astrazeneca Ab | Compuestos quimicos |
| WO2006067445A2 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Csf-1r kinase inhibitors |
| JP5253815B2 (ja) | 2005-01-14 | 2013-07-31 | ケモセントリックス， インコーポレイテッド | ヘテロアリールスルホンアミドおよびｃｃｒ２ |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| EP1683796A1 (en) | 2005-01-24 | 2006-07-26 | Schering Aktiengesellschaft | Pyrazolopyridines, their preparation and their medical use |
| JP2008528580A (ja) | 2005-01-27 | 2008-07-31 | アストラゼネカ・アクチエボラーグ | Ｐ２ｘ７受容体の阻害剤である新規二環式芳香族化合物 |
| US7888374B2 (en) | 2005-01-28 | 2011-02-15 | Abbott Laboratories | Inhibitors of c-jun N-terminal kinases |
| US20060178388A1 (en) | 2005-02-04 | 2006-08-10 | Wrobleski Stephen T | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
| US20070135437A1 (en) | 2005-03-04 | 2007-06-14 | Alsgen, Inc. | Modulation of neurodegenerative diseases |
| US20060235028A1 (en) | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
| EP1879548A2 (en) | 2005-05-13 | 2008-01-23 | Ciba Specialty Chemicals Holding Inc. | Process for coloring keratin fibers comprising metal complexes |
| WO2006128172A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating b cell regulated autoimmune disorders |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| BRPI0613535A2 (pt) | 2005-06-02 | 2011-01-18 | Bayer Cropscience Ag | derivados de heteroarila substituìda por fenilalquila |
| AU2006258101A1 (en) | 2005-06-09 | 2006-12-21 | Merck Sharp & Dohme Corp. | Inhibitors of checkpoint kinases |
| WO2006137772A1 (en) | 2005-06-20 | 2006-12-28 | Astrazeneca Ab | New physical form of n,n´- disubstituted oxabispidines |
| ATE455103T1 (de) | 2005-06-24 | 2010-01-15 | Bristol Myers Squibb Co | Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate |
| WO2007005510A1 (en) | 2005-06-30 | 2007-01-11 | Janssen Pharmaceutica N.V. | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| FR2892412B1 (fr) | 2005-10-26 | 2008-05-16 | Galderma Res & Dev | Composes biaromatiques modulateurs des ppars |
| TW200804307A (en) | 2005-10-27 | 2008-01-16 | Synta Pharmaceuticals Corp | Process for preparing mesylate salts of IL-12 inhibitory compounds |
| EP1945617B1 (en) | 2005-11-03 | 2012-12-26 | Merck Sharp & Dohme Corp. | Histone deacetylase inhibitors with aryl-pyrazolyl motifs |
| EP2404919B1 (en) | 2005-11-08 | 2013-08-21 | Vertex Pharmaceuticals Incorporated | Heterocyclic compound useful as a modulator of ATP-binding cassette transporters. |
| WO2007055374A1 (ja) | 2005-11-14 | 2007-05-18 | Mitsubishi Tanabe Pharma Corporation | 骨粗鬆症治療剤 |
| AR057579A1 (es) | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
| JP5144532B2 (ja) | 2005-11-30 | 2013-02-13 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｃ−Ｍｅｔ阻害剤及び用法 |
| AU2006328602B2 (en) | 2005-12-23 | 2012-05-31 | F. Hoffmann-La Roche Ag | Aryl-isoxazolo-4-yl-oxadiazole derivatives |
| AU2007208495A1 (en) | 2006-01-12 | 2007-08-02 | Merck Sharp & Dohme Corp. | Hydroxyalkylarylamide derivatives |
| US20090012075A1 (en) | 2006-01-12 | 2009-01-08 | Miller Thomas A | Fluorinated Arylamide Derivatives |
| TW200813015A (en) | 2006-03-15 | 2008-03-16 | Mitsubishi Pharma Corp | 2-(cyclic amino)-pyrimidone derivatives |
| JP2007283748A (ja) | 2006-03-23 | 2007-11-01 | Fujifilm Corp | 光記録媒体および可視情報記録方法 |
| PL2656841T3 (pl) | 2006-03-27 | 2017-01-31 | The Regents Of The University Of California | Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym |
| ES2452820T3 (es) | 2006-04-07 | 2014-04-02 | Methylgene, Inc. | Derivados de benzamida como inhibidores de histona desacetilasa |
| JPWO2007125984A1 (ja) | 2006-04-28 | 2009-09-10 | 日本農薬株式会社 | イソキサゾリン誘導体及び有害生物防除剤並びにその使用方法 |
| JP2009535388A (ja) | 2006-05-03 | 2009-10-01 | アストラゼネカ アクチボラグ | ピラゾール誘導体、及びそのｐｉ３ｋ阻害薬としての使用 |
| CN101484452A (zh) | 2006-05-03 | 2009-07-15 | 阿斯利康(瑞典)有限公司 | 噻唑衍生物及其作为抗肿瘤药物的用途 |
| US20080064871A1 (en) | 2006-05-26 | 2008-03-13 | Japan Tobacco Inc. | Production Method of Nitrogen-Containing Fused Ring Compounds |
| CA2653506A1 (en) | 2006-05-31 | 2007-12-06 | Galapagos Nv. | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases |
| WO2007143557A2 (en) | 2006-06-02 | 2007-12-13 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal parasitic infections |
| US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| WO2008005457A2 (en) | 2006-06-30 | 2008-01-10 | Sunesis Pharmaceuticals | Pyridinonyl pdk1 inhibitors |
| US8519135B2 (en) | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
| JP2009544611A (ja) | 2006-07-20 | 2009-12-17 | メルク エンド カムパニー インコーポレーテッド | ヒストン脱アセチル化酵素阻害剤としてのリン誘導体 |
| GB0614579D0 (en) | 2006-07-21 | 2006-08-30 | Black James Foundation | Pyrimidine derivatives |
| AU2007275049B2 (en) | 2006-07-21 | 2011-03-03 | Irm Llc | Compounds and compositions as ITPKb inhibitors |
| FR2903985B1 (fr) | 2006-07-24 | 2008-09-05 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| CA2658887C (en) | 2006-07-28 | 2016-08-23 | University Of Connecticut | Fatty acid amide hydrolase inhibitors |
| WO2008016643A2 (en) | 2006-08-01 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
| US20080119457A1 (en) | 2006-08-24 | 2008-05-22 | Serenex, Inc. | Benzene, Pyridine, and Pyridazine Derivatives |
| WO2008024970A2 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Tetrahydroindolone and tetrahydroindazolone derivatives |
| JP2010519174A (ja) | 2006-09-18 | 2010-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｃ−Ｍｅｔの複素環阻害薬およびその使用方法 |
| AP2780A (en) | 2006-10-18 | 2013-09-30 | Pfizer Prod Inc | Biaryl ether urea compounds |
| DE102006050515A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung |
| US7858645B2 (en) | 2006-11-01 | 2010-12-28 | Hoffmann-La Roche Inc. | Indazole derivatives |
| JPWO2008053913A1 (ja) | 2006-11-02 | 2010-02-25 | 塩野義製薬株式会社 | Ｍｍｐ−１３を選択的に阻害するスルホニルウレア誘導体 |
| JP2009023986A (ja) | 2006-11-08 | 2009-02-05 | Pharma Ip | 抗癌剤としてのビアリール誘導体 |
| US20080145816A1 (en) | 2006-12-15 | 2008-06-19 | Hershey Adrienne A | Yankauer suction device |
| SG177911A1 (en) | 2006-12-21 | 2012-02-28 | Nerviano Medical Sciences Srl | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
| FR2910473B1 (fr) | 2006-12-26 | 2009-02-13 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique. |
| AR064660A1 (es) | 2006-12-26 | 2009-04-15 | Mitsubishi Tanabe Pharma Corp | Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras |
| JP2008179068A (ja) | 2007-01-25 | 2008-08-07 | Fujifilm Corp | 光記録媒体および可視情報記録方法 |
| JP2008179067A (ja) | 2007-01-25 | 2008-08-07 | Fujifilm Corp | 光記録媒体および可視情報記録方法 |
| CA2702647C (en) | 2007-01-31 | 2016-03-22 | Ym Biosciences Australia Pty Ltd | Thiopyrimidine-based compounds and uses thereof |
| EA019103B1 (ru) | 2007-03-20 | 2014-01-30 | Кьюрис, Инк. | Конденсированный аминопиридин в качестве ингибиторов hsp90 |
| WO2008115262A2 (en) | 2007-03-20 | 2008-09-25 | Curis, Inc. | Hsp90 inhibitors containing a zinc binding moiety |
| WO2008119015A2 (en) | 2007-03-27 | 2008-10-02 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
| FR2915198B1 (fr) | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
| WO2008129280A1 (en) | 2007-04-20 | 2008-10-30 | Biolipox Ab | Pyrazoles useful in the treatment of inflammation |
| WO2008139152A1 (en) | 2007-05-11 | 2008-11-20 | Sentinel Oncology Limited | N-oxide-containing pharmaceutical compounds |
| SG185285A1 (en) | 2007-06-03 | 2012-11-29 | Univ Vanderbilt | Benzamide mglur5 positive allosteric modulators and methods of making and using same |
| TWI446905B (zh) | 2007-06-05 | 2014-08-01 | Sanofi Aventis | 經取代之苯甲醯基胺基－氫茚－２－羧酸及相關化合物 |
| US8633186B2 (en) | 2007-06-08 | 2014-01-21 | Senomyx Inc. | Modulation of chemosensory receptors and ligands associated therewith |
| US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
| CN101808518A (zh) | 2007-06-27 | 2010-08-18 | 默沙东公司 | 作为组蛋白脱乙酰酶抑制剂的吡啶基和嘧啶基衍生物 |
| UY31281A1 (es) | 2007-08-13 | 2009-03-31 | Aminas, benzamidas y sulfonamidas {[4-(5,6-dimetil-2-piridin-2-il-piridin-3-il) oxipiridin-2-il]amino} sustituidas, sus sales farmacéuticamente aceptables, composiciones contenniéndolas y aplicaciones. | |
| CA2698511C (en) | 2007-09-04 | 2016-10-11 | The Scripps Research Institute | Substituted pyrimidinyl-amines as protein kinase inhibitors |
| US8354383B2 (en) | 2007-09-17 | 2013-01-15 | Enanta Pharmaceuticals, Inc. | 6,11-bridged biaryl macrolides |
| EP2197552B1 (en) | 2007-09-19 | 2012-11-21 | 4Sc Ag | Novel tetrahydrofusedpyridines as histone deacetylase inhibitors |
| WO2009037001A2 (en) | 2007-09-19 | 2009-03-26 | 4Sc Ag | Novel tetrahydrofusedpyridines as histone deacetylase inhibitors |
| EP2203412A4 (en) | 2007-10-16 | 2012-01-11 | Univ Northeastern | MONOACYLGLYCEROLLIPASE HEMMER FOR MODULATION OF CANNABINOIDACTIVITY |
| US20090156825A1 (en) | 2007-11-26 | 2009-06-18 | Heidebrecht Jr Richard W | Fluorescent compounds that bind to histone deacetylase |
| WO2009078992A1 (en) | 2007-12-17 | 2009-06-25 | Amgen Inc. | Linear tricyclic compounds as p38 kinase inhibitors |
| FR2926553B1 (fr) | 2008-01-23 | 2010-02-19 | Sanofi Aventis | Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique |
| WO2009100406A2 (en) | 2008-02-07 | 2009-08-13 | Synta Pharmaceuticals Corp. | Topical formulations for the treatment of psoriasis |
| JP2009209090A (ja) | 2008-03-04 | 2009-09-17 | Mitsui Chemicals Inc | 殺虫剤及び該殺虫剤に含まれる化合物、並びに該化合物の使用方法 |
| CL2009000600A1 (es) | 2008-03-20 | 2010-05-07 | Bayer Cropscience Ag | Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas. |
| WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| PE20091846A1 (es) | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
| US8110576B2 (en) | 2008-06-10 | 2012-02-07 | Plexxikon Inc. | Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications |
| AU2009257635A1 (en) | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | 5H-Pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor |
| JP2011524917A (ja) | 2008-06-20 | 2011-09-08 | メタボレックス， インコーポレイテッド | アリールｇｐｒ１１９作動薬およびその使用 |
| AU2009264242A1 (en) | 2008-06-27 | 2009-12-30 | Novartis Ag | Organic compounds |
| MX2011000392A (es) | 2008-07-11 | 2011-03-01 | Irm Llc | 4-fenoxi-metil-piperidinas como moduladoras de la actividad de gpr119. |
| WO2010007756A1 (ja) | 2008-07-14 | 2010-01-21 | 塩野義製薬株式会社 | Ｔｔｋ阻害作用を有するピリジン誘導体 |
| PE20110105A1 (es) | 2008-07-15 | 2011-02-25 | Novartis Ag | Derivados de heteroarilo como inhibidores de dgat1 |
| CA2735929C (en) | 2008-09-19 | 2013-12-17 | Pfizer Inc. | Hydroxamic acid derivatives useful as antibacterial agents |
| AU2009295855A1 (en) | 2008-09-29 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Antiproliferative compounds |
| WO2010046780A2 (en) | 2008-10-22 | 2010-04-29 | Institut Pasteur Korea | Anti viral compounds |
| US8513242B2 (en) | 2008-12-12 | 2013-08-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
| JP2012513409A (ja) | 2008-12-23 | 2012-06-14 | アボット・ラボラトリーズ | 抗ウイルス化合物 |
| WO2010088574A1 (en) | 2009-01-30 | 2010-08-05 | Sirtris Pharmaceuticals, Inc. | Azabenzimidazoles and related analogs as sirtuin modulators |
| WO2010111527A1 (en) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
| JP5662411B2 (ja) | 2009-03-27 | 2015-01-28 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Ｍｐｓ１キナーゼ阻害剤としてのｎ−アリール−２−（２−アリールアミノピリミジン−４−イル）ピロール−４−カルボキサミド誘導体 |
| JP2012522748A (ja) | 2009-04-01 | 2012-09-27 | ノバルティス アーゲー | ステアロイル−ｃｏａデサチュラーゼ調節用スピロ誘導体 |
| EP2427436B1 (en) | 2009-05-07 | 2013-01-09 | Grünenthal GmbH | Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands |
| JP2011006408A (ja) | 2009-05-29 | 2011-01-13 | Sumitomo Chemical Co Ltd | 神経栄養因子の活性が関与する疾患の治療または予防剤 |
| WO2010144371A1 (en) | 2009-06-08 | 2010-12-16 | Gilead Colorado, Inc. | Alkanoylamino benzamide aniline hdac inihibitor compounds |
| WO2010151747A1 (en) | 2009-06-26 | 2010-12-29 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimine compounds and methods of making and using same |
| WO2011008931A2 (en) | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
| US8415381B2 (en) | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
| EP2521724B1 (en) | 2009-12-11 | 2016-11-23 | Nono Inc. | Agents and methods for treating ischemic and other diseases |
| PL2513140T3 (pl) | 2009-12-16 | 2016-04-29 | Novo Nordisk As | Podwójnie acylowane pochodne glp-1 |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| WO2011119869A1 (en) | 2010-03-24 | 2011-09-29 | Medical University Of South Carolina | Compositions and methods for the treatment of degenerative diseases |
| EP2842944B1 (en) | 2010-04-06 | 2017-03-15 | Nippon Soda Co., Ltd. | Method for producing nitrogen-containing heterocyclic compound |
| US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| US8217044B2 (en) | 2010-04-28 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone pyrrolidines |
| KR101813931B1 (ko) | 2010-06-30 | 2018-01-02 | 아이언우드 파마슈티컬스, 인코포레이티드 | Sgc 자극제 |
| CN103080106A (zh) | 2010-07-06 | 2013-05-01 | 诺瓦提斯公司 | 用作激酶抑制剂的环醚化合物 |
| US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| WO2012024604A2 (en) | 2010-08-20 | 2012-02-23 | President And Fellows Of Harvard College | High-valent palladium fluoride complexes and uses thereof |
| JP2012107001A (ja) | 2010-10-22 | 2012-06-07 | Shionogi & Co Ltd | インドールアミド化合物を含有する医薬 |
| WO2012061337A1 (en) | 2010-11-02 | 2012-05-10 | Exelixis, Inc. | Fgfr2 modulators |
| RU2582679C2 (ru) | 2010-11-09 | 2016-04-27 | Айронвуд Фармасьютикалз, Инк. | СТИМУЛЯТОРЫ sGC |
| WO2012074050A1 (ja) | 2010-12-01 | 2012-06-07 | 富士フイルム株式会社 | 高分子フィルム、位相差フィルム、偏光板、液晶表示装置、及び化合物 |
| US9427482B2 (en) | 2010-12-21 | 2016-08-30 | Koninklijke Philips N.V. | Agents for clearing biomolecules from circulation |
| AU2011346751A1 (en) | 2010-12-22 | 2013-05-02 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
| US20120184572A1 (en) | 2011-01-13 | 2012-07-19 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
| EP2668162A1 (en) | 2011-01-28 | 2013-12-04 | Novartis AG | Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses |
| US8957066B2 (en) * | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| US20140057953A1 (en) | 2011-03-03 | 2014-02-27 | Rolf Hartmann | Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| AP2013007153A0 (en) | 2011-03-18 | 2013-09-30 | Lupin Ltd | Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators |
| WO2012147890A1 (ja) | 2011-04-27 | 2012-11-01 | 持田製薬株式会社 | 新規アゾール誘導体 |
| WO2012149540A1 (en) | 2011-04-28 | 2012-11-01 | The Broad Institute Inc | Inhibitors of histone deacetylase |
| WO2012154880A1 (en) | 2011-05-09 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases |
| US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| CN103732257A (zh) | 2011-05-16 | 2014-04-16 | 皇家飞利浦有限公司 | 生物正交药物活化 |
| EP2713722B1 (en) | 2011-05-31 | 2017-03-15 | Receptos, LLC | Novel glp-1 receptor stabilizers and modulators |
| JP2013020223A (ja) | 2011-06-17 | 2013-01-31 | Fujifilm Corp | 高分子フィルム、セルロースエステルフィルム、偏光板、及び液晶表示装置 |
| WO2013013815A1 (en) | 2011-07-26 | 2013-01-31 | Grünenthal GmbH | Substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands |
| CA2842983A1 (en) | 2011-07-26 | 2013-01-31 | Grunenthal Gmbh | Substituted heterocyclic aza derivatives |
| WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| US20140162875A1 (en) | 2011-08-12 | 2014-06-12 | Basf Se | N-Thio-Anthranilamide Compounds and Their Use as Pesticides |
| BR112014004845A2 (pt) | 2011-08-30 | 2017-04-04 | Chdi Foundation Inc | pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada |
| JP6165733B2 (ja) | 2011-09-16 | 2017-07-19 | ノバルティス アーゲー | Ｎ−置換ヘテロシクリルカルボキサミド類 |
| WO2013041602A1 (de) | 2011-09-23 | 2013-03-28 | Bayer Intellectual Property Gmbh | Verwendung 4-substituierter 1-phenyl-pyrazol-3-carbonsäurederivate als wirkstoffe gegen abiotischen pflanzenstress |
| EP2766345B1 (en) | 2011-10-14 | 2016-03-16 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| WO2013059648A1 (en) | 2011-10-21 | 2013-04-25 | Neurotherapeutics Pharma, Inc. | 2,3,5 trisubstituted aryl and heteroaryl amino derivatives, compositions, and methods of use |
| WO2013064884A1 (en) | 2011-10-31 | 2013-05-10 | Purdue Pharma L.P. | Quaternized amines as sodium channel blockers |
| US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| EP2833889B1 (en) | 2012-04-04 | 2017-11-01 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| WO2013152727A1 (en) | 2012-04-12 | 2013-10-17 | The University Of Hong Kong | Platinum(ii) complexes for oled applications |
| US20150105433A1 (en) | 2012-04-27 | 2015-04-16 | The Uab Research Foundation | TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM |
| BR112014029501B1 (pt) | 2012-05-31 | 2020-05-19 | Sumitomo Chemical Co | composto heterocíclico fundido, seu uso, agente de controle de pragas e método para o controle de pragas |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| BR112014031068A2 (pt) | 2012-06-12 | 2017-06-27 | Abbvie Inc | derivados piridinona e piridazinona |
| CN106905297A (zh) | 2012-06-15 | 2017-06-30 | 加利福尼亚大学董事会 | 用于脑癌的新颖治疗剂 |
| CN103508961B (zh) | 2012-06-26 | 2015-07-22 | 中美冠科生物技术（太仓）有限公司 | 抗肿瘤药物 |
| US9682970B2 (en) | 2012-06-29 | 2017-06-20 | Biotium, Inc. | Fluorescent compounds and uses thereof |
| KR102178590B1 (ko) | 2012-07-18 | 2020-11-13 | 유니버시티 오브 노트르 담 듀락 | 5,5-헤테로방향족 항-감염 화합물 |
| CN103570625A (zh) | 2012-07-19 | 2014-02-12 | 南京英派药业有限公司 | N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用 |
| WO2014025808A1 (en) | 2012-08-06 | 2014-02-13 | The General Hospital Corporation | Curcumin analogs |
| US20140073634A1 (en) | 2012-08-24 | 2014-03-13 | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center | Heterocyclic modulators of hif activity for treatment of disease |
| WO2014047111A1 (en) | 2012-09-18 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| SG11201502527UA (en) | 2012-10-05 | 2015-04-29 | Rigel Pharmaceuticals Inc | Gdf-8 inhibitors |
| US9775843B2 (en) | 2012-10-11 | 2017-10-03 | Grünenthal GmbH | Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders |
| JP2014101353A (ja) | 2012-10-26 | 2014-06-05 | Shionogi & Co Ltd | オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物 |
| US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
| AU2013342164A1 (en) | 2012-11-09 | 2015-06-04 | Assembly Biosciences, Inc. | Alternative uses for HBV assembly effectors |
| WO2014081301A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Bio-orthogonal drug activation |
| DK2922574T3 (da) | 2012-11-22 | 2023-08-21 | Tagworks Pharmaceuticals B V | Kemisk spaltbar gruppe |
| WO2014081300A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Channel protein activatable liposomes |
| WO2014081299A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Activatable liposomes |
| EP2928891B1 (en) | 2012-12-04 | 2019-02-20 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| CN103864754B (zh) | 2012-12-10 | 2016-12-21 | 中国科学院上海药物研究所 | 五元唑类杂环化合物及其制备方法、药物组合物和用途 |
| US9890127B2 (en) | 2013-03-11 | 2018-02-13 | The Broad Institute, Inc. | Compounds and compositions for the treatment of cancer |
| US9045455B2 (en) | 2013-03-14 | 2015-06-02 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US9944644B2 (en) | 2013-03-14 | 2018-04-17 | The Trustees Of Columbia University In The City Of New York | Octahydropyrrolopyrroles their preparation and use |
| JP2016518316A (ja) | 2013-03-15 | 2016-06-23 | セルジーン アビロミクス リサーチ， インコーポレイテッド | Ｍｋ２阻害剤およびそれらの使用 |
| EA201591532A1 (ru) | 2013-03-15 | 2016-03-31 | Эпизим, Инк. | Ингибиторы carm1 и их применение |
| RU2642454C2 (ru) | 2013-03-20 | 2018-01-25 | Ф. Хоффманн-Ля Рош Аг | Производные мочевины и их применение в качестве ингибиторов белка, связывающего жирные кислоты |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| CN104163792B (zh) | 2013-05-20 | 2017-04-12 | 湖南化工研究院 | N‑吡啶酰胺类化合物及其制备方法与应用 |
| CN104163791B (zh) | 2013-05-20 | 2017-05-03 | 湖南化工研究院 | N‑吡啶（杂）芳酰胺类化合物及其制备方法与应用 |
| AU2014268477A1 (en) | 2013-05-24 | 2015-11-12 | The California Institute For Biomedical Research | Compounds for treatment of drug resistant and persistent tuberculosis |
| CN105682665A (zh) | 2013-05-30 | 2016-06-15 | 华盛顿大学 | 用于治疗细菌性感染的化合物和方法 |
| KR102349659B1 (ko) | 2013-06-10 | 2022-01-11 | 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 | 개질된 방출 스펙트럼을 갖는 인광성 네자리 금속 착물 |
| GB2515785A (en) | 2013-07-03 | 2015-01-07 | Redx Pharma Ltd | Compounds |
| GB2516303A (en) | 2013-07-18 | 2015-01-21 | Redx Pharma Ltd | Compounds |
| US9359330B2 (en) | 2013-08-26 | 2016-06-07 | Purdue Pharma L.P. | Substituted piperidines as sodium channel blockers |
| WO2015031725A1 (en) | 2013-08-30 | 2015-03-05 | President And Fellows Of Harvard College | Transition metal-catalyzed imidation of arenes |
| WO2015035059A1 (en) | 2013-09-06 | 2015-03-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| WO2015051043A1 (en) | 2013-10-01 | 2015-04-09 | Amgen Inc. | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors |
| EP3055287B1 (en) | 2013-10-08 | 2019-11-06 | Lu, Qing-Bin | Non-platinum-based anti-cancer compounds for use in targeted chemotherapy |
| WO2015061247A2 (en) | 2013-10-21 | 2015-04-30 | Merck Patent Gmbh | Heteroaryl compounds as btk inhibitors and uses thereof |
| US9844542B2 (en) | 2013-11-19 | 2017-12-19 | Vanderbilt University | Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mGluR5 |
| CN103601718A (zh) | 2013-12-05 | 2014-02-26 | 江西天人生态股份有限公司 | 一类基于鱼泥丁受体的邻甲酰氨基苯甲酰胺衍生物及其制备方法和用途 |
| WO2015110999A1 (en) | 2014-01-24 | 2015-07-30 | Piramal Enterprises Limited | Ezh2 inhibitors and uses thereof |
| CN103804312B (zh) | 2014-02-17 | 2016-04-20 | 四川百利药业有限责任公司 | 一类氮杂环化合物及其制备方法和用途 |
| WO2015142903A2 (en) | 2014-03-17 | 2015-09-24 | Genentech, Inc. | Method of controlling lactate production with piperdine-dione derivatives |
| GB201405002D0 (en) | 2014-03-20 | 2014-05-07 | Isis Innovation | Fluorination method |
| US9533982B2 (en) | 2014-03-20 | 2017-01-03 | Vanderbilt University | Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators |
| ES2898633T3 (es) | 2014-04-09 | 2022-03-08 | Lumiphore Inc | Macrociclos |
| EP3140298A1 (en) | 2014-05-07 | 2017-03-15 | Pfizer Inc. | Tropomyosin-related kinase inhibitors |
| JP6600319B2 (ja) * | 2014-06-02 | 2019-10-30 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法 |
| WO2016018795A1 (en) | 2014-07-28 | 2016-02-04 | The General Hospital Corporation | Histone deacetylase inhibitors |
| JP2017523204A (ja) | 2014-08-04 | 2017-08-17 | ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｓｉｏｎ Ｍｅｄｉｃａ Ａｐｌｉｃａｄａ | 認知向上のために用いる新規化合物 |
| CA2958193C (en) | 2014-08-18 | 2024-02-27 | Hudson Biopharma Inc. | Spiropyrrolidines as mdm2 inhibitors |
| GB201416513D0 (en) | 2014-09-18 | 2014-11-05 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| US9550778B2 (en) | 2014-10-03 | 2017-01-24 | Vanderbilt University | Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5 |
| EP3204006A4 (en) | 2014-10-08 | 2018-04-04 | Regenacy Pharmaceuticals, LLC | Induction of gata2 by hdac1 and hdac2 inhibitors |
| WO2016058544A1 (en) | 2014-10-16 | 2016-04-21 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| EP3206494A4 (en) | 2014-10-16 | 2018-07-04 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2016100711A1 (en) | 2014-12-18 | 2016-06-23 | The Broad Institute, Inc. | Modulators of hepatic lipoprotein metabolism |
| CN105777632A (zh) | 2015-01-09 | 2016-07-20 | 成都贝斯凯瑞生物科技有限公司 | 芳环并氮杂环衍生物及其应用 |
| JP6800158B2 (ja) | 2015-02-20 | 2020-12-16 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｇｄｆ−８阻害剤 |
| CN106083823A (zh) | 2015-04-30 | 2016-11-09 | 中国科学院上海药物研究所 | 一类具有激酶抑制活性的化合物、制备方法和用途 |
| CA2983314A1 (en) | 2015-04-30 | 2016-11-03 | Memorial Sloan-Kettering Cancer Center | Mitragynine analogs and uses thereof |
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| RS62639B1 (sr) | 2015-07-06 | 2021-12-31 | Alkermes Inc | Hetero-halo inhibitori histonskih deacetilaza |
| US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
| WO2017027984A1 (en) | 2015-08-20 | 2017-02-23 | Simon Fraser University | Compounds and methods for treatment of cancer by inhibiting atg4b and blocking autophagy |
| US10980755B2 (en) | 2015-09-10 | 2021-04-20 | The Regents Of The University Of California | LRH-1 modulators |
| EP3362436B1 (en) | 2015-09-14 | 2021-06-30 | Universiteit Antwerpen | Process for the catalytic directed cleavage of amide-containing compounds |
| WO2017075694A1 (en) | 2015-11-04 | 2017-05-11 | Simon Fraser University | Antibiotic compounds, pharmaceutical formulations thereof and methods and uses therefor |
| TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物 |
| LT3269370T (lt) | 2016-02-23 | 2020-03-25 | Taiho Pharmaceutical Co., Ltd. | Naujas kondensuotas pirimidino junginys arba jo druska |
| US11179710B2 (en) | 2016-03-09 | 2021-11-23 | President And Fellows Of Harvard College | Direct palladium-catalyzed aromatic fluorination |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| CN110049978A (zh) | 2016-11-23 | 2019-07-23 | 雷格南希制药有限责任公司 | 作为选择性hdac1,2抑制剂的哌嗪衍生物 |
| AU2018207402B2 (en) | 2017-01-11 | 2023-09-28 | Alkermes, Inc. | Bicyclic inhibitors of histone deacetylase |
| CN106946890A (zh) | 2017-04-26 | 2017-07-14 | 中国药科大学 | 吡啶类irak4抑制剂、其制备方法及应用 |
| EP3664802B1 (en) | 2017-08-07 | 2022-02-23 | Alkermes, Inc. | Bicyclic inhibitors of histone deacetylase |
| TWI809146B (zh) | 2018-07-13 | 2023-07-21 | 美商羅登醫療公司 | 組蛋白去乙醯酶雙環抑制劑 |
| JP7381578B2 (ja) | 2018-07-13 | 2023-11-15 | アルカーメス，インコーポレイテッド | ヒストンデアセチラーゼの二環式阻害剤 |
-
2018
- 2018-08-07 EP EP18759502.0A patent/EP3664802B1/en active Active
- 2018-08-07 JP JP2020506910A patent/JP7152471B2/ja active Active
- 2018-08-07 SG SG11202000970WA patent/SG11202000970WA/en unknown
- 2018-08-07 CA CA3071861A patent/CA3071861A1/en active Pending
- 2018-08-07 HU HUE18759502A patent/HUE058799T2/hu unknown
- 2018-08-07 AU AU2018313094A patent/AU2018313094A1/en not_active Abandoned
- 2018-08-07 MA MA49839A patent/MA49839B1/fr unknown
- 2018-08-07 DK DK18759502.0T patent/DK3664802T3/da active
- 2018-08-07 WO PCT/US2018/045528 patent/WO2019032528A1/en unknown
- 2018-08-07 MX MX2020001484A patent/MX2020001484A/es unknown
- 2018-08-07 ES ES18759502T patent/ES2914355T3/es active Active
- 2018-08-07 RS RS20220480A patent/RS63343B1/sr unknown
- 2018-08-07 MD MDE20200641T patent/MD3664802T2/ro unknown
- 2018-08-07 LT LTEPPCT/US2018/045528T patent/LT3664802T/lt unknown
- 2018-08-07 PL PL18759502T patent/PL3664802T3/pl unknown
- 2018-08-07 HR HRP20220648TT patent/HRP20220648T1/hr unknown
- 2018-08-07 US US16/636,969 patent/US11225475B2/en active Active
- 2018-08-07 CN CN201880051333.3A patent/CN111032040B/zh active Active
- 2018-08-07 KR KR1020207004809A patent/KR20200037286A/ko active IP Right Grant
- 2018-08-07 SI SI201830672T patent/SI3664802T1/sl unknown
- 2018-08-07 PT PT187595020T patent/PT3664802T/pt unknown
- 2018-08-07 EA EA202090424A patent/EA039417B1/ru unknown
-
2020
- 2020-02-05 IL IL272479A patent/IL272479B2/en unknown
-
2021
- 2021-12-22 US US17/558,840 patent/US11912702B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2914355T3 (es) | 2022-06-09 |
| MA49839B1 (fr) | 2022-05-31 |
| DK3664802T3 (en) | 2022-05-30 |
| RS63343B1 (sr) | 2022-07-29 |
| PL3664802T3 (pl) | 2022-07-11 |
| AU2018313094A1 (en) | 2020-02-20 |
| EA039417B1 (ru) | 2022-01-25 |
| SG11202000970WA (en) | 2020-02-27 |
| CN111032040B (zh) | 2023-08-29 |
| PT3664802T (pt) | 2022-05-24 |
| MX2020001484A (es) | 2020-08-20 |
| WO2019032528A8 (en) | 2019-03-21 |
| IL272479A (en) | 2020-03-31 |
| MD3664802T2 (ro) | 2022-07-31 |
| KR20200037286A (ko) | 2020-04-08 |
| JP7152471B2 (ja) | 2022-10-12 |
| CA3071861A1 (en) | 2019-02-14 |
| EP3664802B1 (en) | 2022-02-23 |
| EP3664802A1 (en) | 2020-06-17 |
| US20210147410A1 (en) | 2021-05-20 |
| US20220340558A1 (en) | 2022-10-27 |
| HUE058799T2 (hu) | 2022-09-28 |
| MA49839A (fr) | 2020-06-17 |
| JP2020530019A (ja) | 2020-10-15 |
| IL272479B2 (en) | 2023-08-01 |
| US11912702B2 (en) | 2024-02-27 |
| LT3664802T (lt) | 2022-06-27 |
| CN111032040A (zh) | 2020-04-17 |
| IL272479B1 (en) | 2023-04-01 |
| SI3664802T1 (sl) | 2022-10-28 |
| WO2019032528A1 (en) | 2019-02-14 |
| EA202090424A1 (ru) | 2020-05-26 |
| US11225475B2 (en) | 2022-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220223T1 (hr) | Biciklički inhibitori histon deacetilaze | |
| HRP20220648T1 (hr) | Biciklički inhibitori histonske deacetilaze | |
| HRP20180109T1 (hr) | Inhibitori gsk-3 | |
| HRP20210526T1 (hr) | Oksisteroli i postupci za njihovu uporabu | |
| HRP20170654T1 (hr) | Makrociklički deaza-purinoni za liječenje virusnih infekcija | |
| HRP20211728T1 (hr) | Rsv antivirusni pirazolo- i triazolo-pirimidinski spojevi | |
| BRPI0507041A (pt) | composto derivados de sulfonamida para o tratamento de doenças seus usos, processo para a preparação dos compostos e combinação de compostos | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| HRP20221495T1 (hr) | Farmaceutske kompozicije koje sadrže derivate imidazotiadiazola i imidazopiridazina kao inhibitore proteazom aktiviranih receptora 4 (par4) za liječenje agregacije trombocita | |
| JP2016147915A5 (hr) | ||
| MX2017013483A (es) | Compuestos y su uso como inhibidores de ?-secretasa 1 (bace1). | |
| JP2011520992A5 (hr) | ||
| UY30411A1 (es) | Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
| WO2017090039A3 (en) | Pharmaceutical compositions comprising levodopa amide and uses thereof | |
| HRP20170359T1 (hr) | Kamsilatna sol (1r,1'r,4r)- 4-metoksi-5"-metil-6'-[5-(prop-1-in-1-il)piridin- 3-il]-3'h-dispiro[cikloheksan-1,2'-inden-1'2'-imidazol]-4"-amina i njezini kristalni oblici za liječenje [beta]-povezanih patologija kao što je npr. alzheimerova bolest | |
| HRP20220029T1 (hr) | Supstituirani derivati ksantina | |
| NI201600160A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
| HRP20221098T1 (hr) | Tretman kognitivnih i simptoma poremećaja raspoloženja kod neurodegenerativnih i neuropsihijatrijskih poremećaja agonistima gabaa receptora koji sadrže alfa5 | |
| HRP20211907T1 (hr) | Pirazol – oksazolidinon spoj za anti – hepatitis b virus | |
| HRP20120913T1 (hr) | Derivati 4-alkoksipiridazina kao brzo disocirajuä†i antagonisti dopamin 2 receptora | |
| CA2864606C (en) | Methods of treating and preventing diseases and disorders of the central nervous system | |
| DOP2016000289A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
| JP2018526345A5 (hr) | ||
| WO2018027037A3 (en) | Reelin compositions for treatment of neurological disorders | |
| RU2019128576A (ru) | Сокристаллы замещенных глициновых соединений и их применение |